← Back to Search

Radiopharmaceutical

Phosphorus 32 for Glioblastoma

Phase 1

Waitlist Available

Research Sponsored by Center for Molecular Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No clinical evidence of metastatic disease within the CNS other than the primary tumor site

Performance status Karnofsky 70-100%

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing the side effects and best dose of phosphorus 32 to treat glioblastoma multiforme.

Who is the study for?

This trial is for adults with grade 4 astrocytoma (glioblastoma) who have not responded to radiotherapy or surgery, or have a poor prognosis. They must have adequate kidney and blood function, be able to perform daily activities well (Karnofsky score of 70-100%), use contraception if fertile, and not be pregnant. The tumor should measure 3 to 5 cm without evidence of spread within the CNS.Check my eligibility

What is being tested?

The study is testing the safety and optimal dosage of a radioactive drug called phosphorus 32 in patients with glioblastoma multiforme. It aims to determine how well this treatment can kill tumor cells in those who've had unsuccessful prior treatments or are considered high-risk.See study design

What are the potential side effects?

Potential side effects from phosphorus 32 may include damage to healthy brain tissue leading to neurological deficits, fatigue due to radiation exposure, hair loss at the treatment site, nausea, headaches, and potential risks associated with radioactive therapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has not spread to my brain or spinal cord.

Select...

I am mostly able to care for myself and carry out daily activities.

Select...

My lesion is between 3 to 5 cm in size.

Select...

My previous treatments like surgery or radiotherapy didn't work, or my disease is expected to not improve.

Select...

I do not have any tumors in my spinal cord.

Select...

I am 18 years old or older.

Select...

I have been diagnosed with grade 4 glioblastoma.

Select...

I had a precise biopsy or surgery but still have some tumor left.

Select...

My kidney function tests are within normal limits.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

Center for Molecular MedicineLead Sponsor

5 Previous Clinical Trials

201 Total Patients Enrolled

Stanley E. Order, MD, ScD, FACRStudy ChairCenter for Molecular Medicine

1 Previous Clinical Trials

48 Total Patients Enrolled

Media Library

Phosphorus 32 (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT00004129 — Phase 1

Brain Tumor Clinical Trial 2023: Phosphorus 32 Highlights & Side Effects. Trial Name: NCT00004129 — Phase 1

Phosphorus 32 (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004129 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research effort currently available to participants?

"It appears that clinicaltrials.gov does not indicate any active recruitment for this trial, which was initially listed in September 1999 and last revised on the 16th of 2013. Nevertheless, there are presently 544 medical studies searching for participants."

Answered by AI